Klin Farmakol Farm. 2017;31(3):19-22 | DOI: 10.36290/far.2017.033
Antiresorptive substances and osteonecrosis of the jaws from point of view of stomatology
- Klinika stomatológie a maxilofaciálnej chirurgie Lekárskej fakulty Univerzity Komenského
- a Onkologického ústavu svätej Alžbety, s. r. o., Bratislava
Significant group of antiresorptive substances are bisphosphonates (abbr. BP). They inhibit diferentiation and maturationof osteoclasts, decrease bone resorption. Main indications of the BP are multiple myeloma, Paget´s disease, bone metastasesby cancer of prostata, breast cancer, kidney malignancies etc. and by osteoporosis. As negative effect of the BP revealsdevelopment of jaw osteonecrosis in some cases, by the American Association for Oromaxilofacial Surgery named BRONJ –bisphosponate related osteonecrosis of the jaws or MRONJ – medication related osteonecrosis of the jaws respectively.Incidence of the osteonecrosis by oral use of the BP is above 1 percent or less, by intravenous application ranges from 1 to10 percents.Therapy of the developed BRONJ/MRONJ is complicated and long lasting. Therefore the prevention is prefered by sanation of teethand the oral cavity before start of the BP treatment. Close cooperation is required within the general physician who prescribesthe antiresorptive substances and the dentist.Very positive is when the annoucement of the need of consultation with the dentist of the patient is made by the pharmacist.
Keywords: bisphosphonates, BRONJ, MRONJ, osteonecrosis of the jaws
Received: June 28, 2019; Accepted: August 20, 2019; Prepublished online: August 20, 2019; Published: November 1, 2017 Show citation
References
- Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) Induced avascular necrosis of the jaws: agrawing epidemic. J of Oral and der Maxillofacial Surgeons. 2003; 61(9): 1115-1117.
Go to original source... 
Go to PubMed... - Skripitz R, Kurth A, Roth A. Medikamentóse Verbesserung der Implantateinheilung. Der Orthopäde 2015; 9(44): 703-709. Go to original source... Go to PubMed...
- Vohra F, Mohammad Qasim Al-Rifaiy, Amas K, Javed F: Efficacy of systemic bisphosphonate delivery on osseointegration of implants osteoporotic conditions: Lessons from animal studies. Archives oral biology. 2014; 59: 912-920. Go to original source... Go to PubMed...
- Borm JM, Moser S, Demerau G, Stadlinger B, Grätz K W, Jacobsen Ch. Risikobeurteilung von Patienten mit ossärer, antiresorptiver Therapie in der zahnärztlichen Praxis. Schweiz Monatschr Zahnmed. 2013; 123: 11.
- Koy S, Schubert M, Koy J, Ney M, Lauer G, Sabatowski R. Bisphosphonat - assoziierte Kiefernekrosen. Schmerz 2015; 29: 171-178. Go to original source... Go to PubMed...
- Pasoff M. C-Terminal Cross-Linking Telopeptide as a Serologic Marker for Bisphosphonate-Related Osteonecrosis of the Jaw: Review of 2 Cases J. Can Dent Assoc 2013; 79: d51. Go to PubMed...
- Ruckhäberle E. Orale Bisphosphonate senken möglicherweise die Inzidenz von postmenopausalen Korpuskarzinomen. Strahlenther Onkol 2015; 191: 759-760. Go to original source...
- Farahmand P, Spiegel R, Ringe JD. Männliche Osteoporose. Z Rheumatologie 2016; 75: 459-465. Go to original source... Go to PubMed...
- Svejda B, Muschitz Ch, Gruber R, Brundtner Ch, Svejda Ch, Gasser RW, Santler G. Positionspapier zur medikamentenassoziierten Osteonekrose des Kiefers (MRONJ), Wien. Med Wochenschr 2016; 166: 68-74. Go to original source... Go to PubMed...
- Pichardo Sarina EC, Richar van Merkesteyn. Bisphosphonate related osteonecrosis of the jaws: spontaneus or dental origin? Oral and maxiloofacial surgery 2013; 116(3) Sept.
- Cella L, Appici A, Arbasi M, et al: Autologous bone marrow stem cell intralesional transplantation repairing bisphoshonate related osteonecrosis of the jaw. Head and Face Medicine 2011; 7: 16. Go to original source... Go to PubMed...
- Matsuo A, Hamada H, Takahashi H, Okomato A, Kaise H, Chikazu D. Evalution of dental implants as a risk factor for the development of the jaw in breast cancer patients. Odontology, The Society of the Nippon Dental University 2015. Go to original source...
- Sibert T, Jurkovic R, Stalelova D, Strecha J. Immediate implant placement in a patient with osteoporosis undergoing bisphosphonate therapy: 1-year Preliminary prospective study. J Oral Implantol, July 1, 2015; 41(Spec No): 360-365. Go to original source... Go to PubMed...
- Holzinger D, Seeman R, Matoni N, Ewers R, Millesi W, Wutzl A. Effect of Dental Implants on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 2014; 72: 1937. e1-1937. e8. Go to original source... Go to PubMed...
- Walter Ch, Al-Nawas B, Wolff T, Schiegnitz E, Grótz K A. Dental implants in patients treated with antiresorptive medication - a systematic literature review. International Journal of Implant Dentistry 2016; 2: 9. Go to original source... Go to PubMed...
- Mattheos N, Caldwell P, PetcuE B, Ivanovski S. Dental Implant Placement with Bone Augmentation in a Patient Who Received Intravenous Bisphosphonate Treatment for Osteoporosis. J Can Dent Assoc 2013; 79: d2. Go to PubMed...
- Orris I R, Key M L, Arnett TR. Bisphosphonates inhibit osteoblast growth and bone formation. Department of Anatomy and Biology, University College London.
- Kaušitz J, Ondruš D, a kol. Všeobecná onkológia, SOLEN s. r. o., Bratislava 2017; 1. vydanie, s. 510-514.